Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Sorafenib inhibits many kinase mutations associated with drug-resistant gastrointestinal stromal tumors.

Molecular cancer therapeutics - 1 Aug 2012

Heinrich Michael C, Marino-Enriquez Adrian, Presnell Ajia, Donsky Rachel S, Griffith Diana J, McKinley Arin, Patterson Janice, Taguchi Takahiro, Liang Cher-Wei, Fletcher Jonathan A

Abstract excerpt

Sorafenib has substantial clinical activity as third- or fourth-line treatment of imatinib- and sunitinib-resistant gastrointestinal stromal tumors (GIST). Because sorafenib targets both angiogenesis-related kinases (VEGFR) and the pathogenetic kinases found in GIST (KIT or PDGFRA), the molecular basis for sorafenib efficacy in this setting remains unknown. We sought to determine the spectrum of activity of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Benzenesulfonates

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gastrointestinal Stromal Tumors

Share to Imatinib Mesylate

Share to Inhibitory Concentration 50

Share to Niacinamide

Share to Phenylurea Compounds

Share to Sorafenib

Source

Open in PubMed Open full text

Identifiers

PMID: 22665524
DOI: 10.1158/1535-7163.MCT-12-0223
PMCID: PMC3992122

Genes

KIT
PDGFRA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sorafenib inhibits many kinase mutations associated with drug-resistant gastrointestinal stromal tumors.PMID 22665524Read ↗

Spectrum of activity of dasatinib against mutant KIT kinases associated with drug-sensitive and drug-resistant gastrointestinal stromal tumors.Semantic proximity Read ↗

The role of KIT in the management of patients with gastrointestinal stromal tumors.Semantic proximity Read ↗

Sorafenib inhibits imatinib-resistant KIT and platelet-derived growth factor receptor beta gatekeeper mutants.Semantic proximity Read ↗

Mechanisms of resistance to imatinib and sunitinib in gastrointestinal stromal tumor.Semantic proximity Read ↗

Resistance to Tyrosine Kinase Inhibitors in Gastrointestinal Stromal TumorsSemantic proximity Read ↗

Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.Semantic proximity Read ↗

Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor.Semantic proximity Read ↗

KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients.Semantic proximity Read ↗

The ability of sorafenib to inhibit oncogenic PDGFRbeta and FLT3 mutants and overcome resistance to other small molecule inhibitors.Semantic proximity Read ↗

Emerging Agents for the Treatment of Advanced, Imatinib-Resistant Gastrointestinal Stromal Tumors: Current Status and Future Directions.Semantic proximity Read ↗

KIT mutations in GIST.Semantic proximity Read ↗

The BRAF Status May Predict Response to Sorafenib in Gastrointestinal Stromal Tumors Resistant to Imatinib, Sunitinib, and Regorafenib: Case Series and Review of the Literature.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.